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According to the authors and editors, this report contains the most justified principles of diagnostic and therapeutic 
procedures prepared considering the scientific value of evidence and category of recommendations. These principles 
should always be interpreted in the context of an individual clinical situation. The recommendations do not always 
correspond to the current reimbursement rules in Poland. In case of doubt, the current possibilities of reimbursement 
of individual procedures should be established.
1.  The quality of scientific evidence
 I — Scientific evidence obtained from well-designed and conducted randomized clinical trials or meta-analyses of 
randomized clinical trials
 II —  Scientific evidence obtained from well-designed and conducted prospective observational studies (non-rando-
mized cohort studies)
 III — Scientific evidence obtained from retrospective observational studies or case-control studies
 IV — Scientific evidence obtained from clinical experiences and/or experts, opinions
2.  Category of recommendations
 A — Indications confirmed unambiguously and absolutely useful in clinical practice
 B — Indications probable and potentially useful indications in clinical practice
 C — Indications determined individually
Introduction
Nausea and vomiting (N&V) constitute the side 
effects of anticancer therapy and are particularly fre-
quent during chemotherapy (CTH) and radiotherapy 
(RT). Prevention and alleviation of the intensity of 
N&V is important due to the negative impact on 
quality of life (including decreased motivation to 
continue therapy and, in extreme cases, resignation 
from therapy) as well as a risk of development of 
fluid-electrolyte imbalance, loss of appetite, and wors-
ening of the patient’s performance status. 
54
OncOlOgy in clinical practice 2018, Vol. 14, No. 2
Table 1. Intensity of nausea according to WHO criteria [4]
Grade I        Grade II       Grade III       Grade IV Grade V
Loss of appetite without 
alteration in eating 
habits
Oral intake decreased 
without significant 
weight loss, 
dehydration,  
or malnutrition
Disorders of oral intake 
of liquids and solid 
foods
No oral caloric intake,
severe nausea, 
the symptoms are continuous
    Death
Appropriate prevention of N&V is the most ef-
fective method of reducing the risk of developing the 
above-mentioned consequences of N&V.
Chemotherapy-induced nausea and 
vomiting
Depending on the administered CTH regimen and 
some other patient- and therapy-dependant factors, 
N&V may occur in 70–80% of patients who do not 
receive prophylactic antiemetic therapy. The classifica-
tion, which is based on the length of the interval between 
the administration of CTH and the onset of N&V [1, 2] 
differentiates the following types of N&V:
 — early (occurring in the first 24 hours, usually after 
several minutes to several hours after administra-
tion of CTH and achieving maximal intensity after 
5–6 hours);
 — late (occurring after 24 hours and usually achieving 
maximal intensity 48–72 hours after administration 
of CTH and persisting for 3–7 days);
 — anticipatory (occurring before the administration 
of a consecutive dose of CTH, affecting 20–60% 
of patients and usually consisting of nausea with-
out vomiting).
The occurrence of early N&V is a risk factor of de-
layed symptoms. However, in 25% of patients late N&V 
are seen without acute symptoms. Sometimes late N&V 
becomes persistent and continues for up to several days 
(so-called prolonged N&V) [1, 2].
The anticipatory N&V is usually related to some 
psychogenic factors and affects patients in whom the 
previous antiemetic management was not effective. 
Stimulation of the cortical centres is a key factor in 
this type of N&V, and the classical antiemetic drugs 
are ineffective (except for anxiolytics). In this situa-
tion, drugs with an unspecific mechanism of activity, 
directed towards the type 1 histamine receptors may 
be additionally used. 
All types of N&V may be accompanied by general 
symptoms (anxiety sensation, excessive sweatening, in-
creased saliva secretion, vertigo, loss of appetite or anorexia 
associated with anxiety about the occurrence of N&V, sen-
sation of fullness in stomach even after small meals) [1, 2].
Pathogenesis and risk factors
The pathomechanism is complex and specific for 
a particular type of N&V. Generally, activation of the 
trigger centre in the area located in the fundus of the 
IV chamber and of the brain trunk (area postrema) 
results in N&V. The activation of the trigger zone in 
the central nervous centre (CNS) is a result of direct 
activation of the receptors by the factors delivered by 
blood or by the cerebrospinal fluid, or of the indirect 
activation through the vagus nerve of the receptors 
in the pharynx and in the gastrointestinal tract. The 
activation of the trigger centre may also occur during 
the stimulation of the vestibular apparatus (typical 
for the platinum derivatives) or through the stim-
ulation of the cortical centres (psychogenic effect, 
olfactory and vision disturbances). The transduction 
of the signal of the emetic reaction, except for the 
type induced by stimulation of the cortical centres, 
is done by numerous neurotransmitters (serotonin, 
dopamine, acetylcholine, histamine, neurokinin, or 
noradrenaline) [2]. Preventive management is based 
on the mechanism of induction of N&V. The concept 
of this approach is to interrupt the reaction through 
the inhibition of the activity of the receptors of the 
individual neurotransmitters. 
The most important neurotransmitters and receptors 
that cause early N&V include primarily serotonin [5-hy-
droxytryptamine (5-HT)] and serotonin receptor type 3 
(5-HT3) as well as dopamine and dopamine receptor 
type 2 (D2). The introduction into clinical practice 
5-HT3 antagonists agents that block the binding of 
5-HT to 5-HT3 receptor) increased the efficacy of the 
prevention of early vomiting and — to a lesser extent 
— of nausea. The drugs that block the D2 receptor are 
less efficient (especially in the case of the CTH with high 
and moderate emetogenic potential), and in addition 
they induce some important side effects [1–3].
The pathomechanism of the late N&V is different, 
which is confirmed by weak efficacy of the 5-HT3 recep-
tor antagonists. Substance P plays a major role in the 
transduction of the signal stimulating the emetogenic 
reaction. Substance P is a neuropeptide that binds to 
neurokinin receptor type 1 (NK-1), which through neu-
rokinin may activate the trigger centre in the CNS. The 
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Table 2. Intensity of the vomiting according to the WHO criteria [4]
Grade I   Grade II         Grade III    Grade IV Grade V
1 episode in 24 hours 2–5 episodes  
in 24 hours
> 6 episodes in 24 hours > 10 episodes  
in 24 hours
    Death
Table 3. The emetogenic potential (risk) of the anticancer drugs [3, 4]
Risk group Frequency Drug/dose
High > 90% Chlormethine, cisplatin, cyclophosphamide ≥ 1500 mg/m2, dacarbazine, doxorubicin ≥ 60 mg/m2, 
epirubicin > 90 mg/m2, iphosphamide ≥ 10 g/m2, carmustine > 250 mg/m2, streptozotocin, 
procarbazine, and all schedules including anthracycline and cyclophosphamide (e.g. AC, FAC, TAC)
Moderate 30–90% Aldesleukin > 12 mln IU/m2, alemtuzumab, altretamine, amifostine > 300 mg/m2,  
azacitidine, bendamustine, bosutinib, busulfan, ceritinib, cyclophosphamide < 1500 mg/m2,  
cytarabine > 1000 mg/m2, dactinomycin, daunorubicin, doxorubicin < 60 mg/m2, epirubicin ≤ 90 mg/m2,  
estramustine, hexamethylmelamine, idarubicin, imatinib, ifosfamide < 10 g/m2,  
interferon alfa ≥ 10 mln IU/m2, interleukin-2 > 12–15 mln IU/m2, irinotecan, carboplatin, 
carmustine ≤ 250 mg/m2, clofarabine, crizotinib, lomustine, melphalan, methotrexate ≥ 250 mg/m2, 
mitotane, oxaliplatin, temozolomide, arsenictrioxide, trabectedin, trifluridine-tipiracil, vinorelbine 
(oral formulation)
Low 10–30% Afatinib, aflibercept, axitinib, aldesleukin ≤ 12 mln IU/m2, emetasinealdo-trastuzumab, 
amifostine < 300 mg/m2, atezolizumab, bortezomib, brentuximab, cetuximab, 
cytarabine ≤ 1000 mg/m2, dabrafenib, dasatinib, docetaxel, liposomal doxorubicin, eribulin, 
etoposide, everolimus, floxuridine, fludarabine, fluorouracil, gemcitabine, ibrutinib, ixabepilone, 
interferon alfa 5–10 mln IU/m2, cabazitaxel, liposomal formulation of irinotecan, ipilimumab, 
capecitabine, carfilzomib, lapatinib, lenalidomide, methotrexate > 50 mg/m2 as well as < 250 mg/m2,  
mitomycin, mitoxantrone, nilotinib, olaparib, paclitaxel (conventional and liposomal formulation), 
pazopanib, pemetrexed, pentostatin, regorafenib, sunitinib, thiotepa, topotecan, vinflunine
Minimal < 10% Alectinib, alemtuzumab, asparaginase, bevacizumab, bleomycin, chlorambucil (orally), 
cytarabine < 100 mg/m2, daratumumab, dasatinib, dexrazoxane, erlotinib, everolimus, fludarabine, 
gefitinib, hydroxyurea (oral formulation), interferon alfa < 5 mln IU/m2, cabozantinib, cladribine, 
melphalan (oral formulation), lapatinib, lenalidomide, mercaptopurine, methotrexate < 50 mg/m2, 
nelarabine, nilotinib, nivolumab, ofatumumab, osimertinib, palbociclib, panitumumab, pazopanib, 
pentostatin, pomalidomide, ramucirumab, rituximab, sorafenib, thalidomide, temsirolimus, 
tioguanine, trastuzumab, trametinib, vandetanib, vemurafenib, vinblastine, vindezine, vincristine, 
vinorelbine (intravenous formulation), vismodegib, vorinostat
Levels of evidence and grades of recommendations — I, A
inhibitors of the NK-1 receptor are effective in the pre-
vention of late N&V, and their activity in the prevention 
of acute N&V indicates that substance P and receptor 
NK-1 influence the occurrence of acute symptoms. The 
pathogenesis of late N&V also depends — although to 
a lesser extent — on some other neurotransmitters (e.g. 
dopamine and noradrenaline) as well as on some addi-
tional mechanisms that directly stimulate the CNS (e.g. 
transitional oedema of the brain after administration of 
platinum derivatives) [1–4].
The intensity of N&V is classified according to the 
World Health Organisation (WHO) (Tab. 1 and 2) [1]. 
Assessment of the expected severity of N&V during the 
CTH is crucial in determining the appropriate man-
agement.
The intensity of N&V depends mostly on the risk of 
symptoms occurrence (so-called emetogenic potential) 
after the administration of each particular anticancer 
drug in patients who do not receive prophylactic man-
agement [3–5]. The drugs may have a high (> 90%), 
moderate (30–90%), low (10–30%), or minimal 
(< 10%) emetogenic risk (II, A) (Tab. 3). The afore-
mentioned emetogenic risk groups are mainly related 
to early N&V. The combination of two or more drugs 
(e.g. anthracyclines and alkylating agents in an AC 
regimen) may result in a synergistic increase of the 
emetogenic risk. In multidrug schedules the expected 
emetogenic risk is determined by the drug with the 
highest emetogenic potential. The emetogenic potential 
of the individual drug is of no importance for high-dose 
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CTH, that represents a high emetogenic potential inde-
pendently from the used schedule. Due to a different 
mechanism, the above-presented classification does not 
apply to anticipatory N&V. The classification of N&V 
risk is actualised in parallel with the introduction of 
new anticancer drugs. 
Except for the emetogenic potential of the used 
drugs, the risk of the occurrence of N&V depends on 
the patient’s characteristics. Young persons and females 
(especially females who have a history of severe vom-
iting during pregnancy), as well as persons with travel 
sickness and the presence of so-called spontaneous 
morning sickness, have a higher predisposition to 
develop N&V and lower efficacy of the preventive 
management. A lower tendency to develop intensive 
N&V is observed in patients with strong motivation 
to receive anticancer treatment and in good general 
condition as well as in patients who have a history of 
alcohol abuse (over 100 grams of ethanol per day). 
The tolerance of previously administered CTH is 
a good predictor of the intensity of N&V. A role in 
predicting N&V intensity has a tolerance of prior 
CTH; a risk is higher in case of previous symptoms, 
whereas good control of N&V during previous CTH 
may result in less intense symptoms (including — low 
risk of anticipatory N&V. All the above listed factors 
should constitute a basis to define the risk of N&V in 
an individual patient and to choose the appropriate 
management as well as to modify antiemetic therapy 
during chemotherapy [6].
Antiemetic drugs
Basic antiemetic therapies are 5-HT3 receptor an-
tagonists, NK-1 receptor antagonists and corticosteroids 
(Tab. 4).
Serotonin 5-HT3 receptor antagonists 
The individual drugs from the group of 5-HT3 re-
ceptor antagonists (setrons) have different chemical 
structure and pharmacokinetic parameters, but they are 
characterised by a similar activity and toxicity profile 
(palonosetron constitutes an exception due to higher 
affinity to the receptor and a longer half-life compared 
to ondansetron and other 5-HT3 antagonists). The 
higher efficacy of the 5-HT3 antagonists compared 
Table 4. Antiemetic drugs from the 5-HT3 i NK-1 antagonists group and corticosteroids
Drug Usualdosing Administration schedule
5-HT3 antagonists
Dolasetron 100 mg p.o. 1 hour prior to CTH — day 1
Granisetron 1 mg or 0.01 mg/kg i.v. 1 hour prior to CTH — day 1
1–2 mg p.o. 1 hour prior to CTH — day 1
Ondansetron 8 mg or 0.15 mg/kg i.v. 1 hour prior to CTH — day 1
8–16 mg p.o. Every 12 hours — day 1
Tropisetron 5 mg i.v. 1 hour prior to CTH — day 1
5 mg p.o. 1 hour prior to CTH — day 1
Palonosetron 0.25 mg i.v.
0,5 mg p.o.
1 hour prior to CTH — day 1
0.5 mg p.o.(product containing palonosetron 
and netupitant)
1 hour prior to CTH — day 1
NK-1 antagonists
Aprepitant 125 mg p.o. on day 1 1 hour prior to CTH — day 1
80 mg p.o. Day 2 and day 3
Netupitant 300 mg p.o. in combination with palonosetron 
0.5 mg p.o. (the product containing both drugs) 
— day 1
1 hour prior to CTH — day 1
Corticosteroids
Dexamethasone 8–12 mg i.v. or p.o. 0.5–1 hour prior to CTH — day 1
8–16 mg p.o.* Days 2–4
Methylprednisolone 40–125 mg i.v. 1 hour prior to CTH
*In patients receiving the NK-1 antagonists, use of dexamethasone is recommended in a dose of 8–12 mg on day 1 and 8 mg on days 2–4; p.o.— orally; 
i.v. — intravenously; CTH — chemotherapy
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to other drugs (e.g. D2 receptor antagonists) in the 
prevention of early N&V induced by CTH of high and 
moderate emetogenic risk (I, A) has also been proven. 
Their activity does not depend on the type of cytotoxic 
agent or on the route and mode of administration of 
the antiemetic drug — intravenous, oral (tablet, syrup), 
transrectal (suppository), or transdermal as well as on 
the dosing schedule (the efficacy of a single daily dose 
and of the multiple divided doses is comparable) [7, 8]. 
The advantage of the 5-HT3 inhibitors over other drugs 
in the prevention of the late N&V has not been demon-
strated. The only exception is palonosetron, which, due 
to its prolonged activity against the 5-HT3 receptor 
prevents early N&V and reduce late symptoms (I, A), 
that has been demonstrated in several clinical studies 
and in a meta-analysis [9]. Drugs that are antagonists 
of 5-HT3 receptors show no activity in the case of the 
anticipatory N&V and emesis caused by factors other 
than anticancer therapy (except for the use of setrons in 
the therapy of postsurgical N&V; indication included in 
the SPC). The side effects of setrons are relatively rare 
and the most common include headaches, transitory and 
mild elevation of liver enzyme activity, and constipation.
The constipation induced by 5-HT3 antagonists 
may significantly influence the quality of life. In case 
of occurrence of this complication the demand for 
setrons should be evaluated and the dose reduction as 
well as addition of a drug with a different antiemetic 
mechanism (e.g. D2 antagonist or dexamethasone) 
considered. Due to the mechanism of setrons-induced 
constipation (paralytic mechanism), classic laxative 
drugs may be ineffective (e.g. lactulose). Provided 
that the opioids have an additive constipatory effect, 
a modification of the analgesic therapy may be con-
sidered [4]. 
After the use of ondansetron and of granisetron 
and dolasetron the electrocardiography (ECG) may 
show some disorders of the sub-form of PR and QT 
prolongation. These disorders usually do not cause 
any symptoms; however, they may sometimes result 
in heart arrhythmia (patients with coexisting cardiac 
arrhythmias and other heart diseases as well as with 
hypokalaemia or hypomagnesemia). Heart condition 
should be monitored in patients with the presence of 
the above-mentioned risk factors, who receive setrons 
[4, 5]. Cardiac disorders have not been observed during 
the administration of palonosetron.
NK-1 receptor antagonists
The mechanism of action of NK-1 receptor antago-
nists, explains their efficacy in the therapy of the early 
and late N&V induced by chemotherapy with a high 
or moderate emetogenic potential [4, 5]. These data 
are confirmed by the results of many randomised clin-
ical trials, which have been summarised in a systemic 
review (I, A) [10]. Among the drugs belonging to the 
discussed group, aprepitant and netupitant (accessible 
as a formulation combined with palonosetron) are 
reimbursed in Poland.
The clinical trials demonstrated higher efficacy of 
the combination of NK-1 antagonist with 5-HT3 inhibi-
tors and with corticosteroids on the first day of therapy 
(I, A) [2, 4, 5, 10, 11]. Aprepitant should be adminis-
tered during three consecutive days (on day 2 and day 
3 in combination with dexamethasone and without any 
5-HT3 antagonist), while a formulation of the netupi-
tant in combination with palonosetron should be used 
only on day 1 (consecutive days — dexamethasone 
only). Both agents are the CYP3A4 enzymes inhibitors 
that require a reduction of the dose of dexamethasone 
(day 1 — 8–12 mg, days 2–4 — 8 mg). For the same rea-
sons, any other drugs should also be used with caution 
(e.g. warfarin). The choice of NK-1 receptor antagonist 
should depend on the convenience of administration 
and cost of therapy, as well as superiority of netupitant 
over aprepitant in terms of better control of N&V, 
which has been proven in head-to-head comparisons.
Corticosteroids
The exact mechanism of the antiemetic activity of 
corticosteroids is unknown. The anti-oedematous effect 
on the CNS matters. Clinical trials have shown that the 
addition of corticosteroids to the other antiemetic drugs 
increases their efficacy [8, 10]. The corticosteroids show 
also some activity in the prevention of late N&V. In 
clinical practice dexamethasone is the most frequently 
used corticosteroid (less frequently — methylpredni-
solone). The typical side effects of corticosteroids are 
not clinically significant in the prevention of N&V due 
to the short period of their administration.
Adjuvant drugs
An adjuvant effect (lower antiemetic activity) is seen 
in receptor D2 antagonists, phenothiazine derivatives, 
butyrophenone derivatives, antihistaminic drugs, and 
benzodiazepines (Tab. 5) [4, 5].
Receptor D2 antagonists 
Metoclopramide is used in clinical practice. The 
main mechanism of metoclopramide activity is inhibition 
of the activity of the D2 receptor; however, this drug also 
has some (significantly lower than setrons) affinity to the 
5-HT3 receptor. The efficacy of metoclopramide in the 
prevention of early N&V induced by chemotherapy with 
a high or moderate emetogenic potential is significantly 
lower than that of setrons. Metoclopramide and setrons 
show similar efficacy in late N&V and complaints in-
duced by chemotherapy with low emetogenic potential. 
Some reversible side effects (dystonic reactions, muscle 
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Table 5. Antiemeticdrugs — adjuvants
Drug Usualdosing Administration route
Metoclopramide 1–2 mg/kg i.v. Before CTH and after 2 hours
Prochlorperazine 10–30 mg i.v. Every 6–8 hours during the CTH
10–20 mg p.o. Every 6–8 hours during the CTH
Chlorpromazine 12.5–50 mg i.v. Every 6–8 hours during the CTH
10–25 mg p.o. Every 6–8 hours during the CTH
Clonazepam 0.5–2 mg i.v. Every 4–6 hours during the CTH
0.5–1 mg p.o. In the evening and in the morning before CTH — anticipatory N&V
Droperidol 1 mg i.v. 15 minutes before CTH and then if necessary every 6 hours
Olanzapine 5–10 mg p.o. 1 × daily on the day of CTH and for 3 days after the completion  
of chemotherapy (prevention)
1 × daily for 3 days (therapy)
Thiethylperazine 6.5 mg p.o.or p.r. Every 4–6 hours during the CTH and after the completion of therapy 
6.5 mg i.v. Every 8–24 hours — severe N&V
p.o. — orally; i.v. — intravenously; p.r. — per rectum; CTH — chemotherapy; N&V — nausea and vomiting 
tremor, and sleepiness) may occur during therapy with 
metoclopramide, especially in young persons. In con-
trast to setrons, metoclopramide does not cause con-
stipation (on the contrary, due to the pro-kinetic effect 
onto the gastrointestinal tract it may sometimes induce 
diarrhoea). The metoclopramide is contraindicated in 
patients with the risk of sub-ileocolitis.
Phenothiazine derivatives
The use of drugs from the group of phenothiazine 
derivatives is limited due to their low antiemetic activity.
Butyrophenone derivatives
The antiemetic activity of butyrophenone consists of 
the inhibition of the D2 receptor; however, the activity 
is lower than that of metoclopramide.
Antihistaminic drugs
They have limited individual activity, but they are 
used in premedication of anticipatory N&V. They are 
also indicated in premedication in case of chemotherapy 
that might induce allergic reactions (toxoids, oxaliplatin).
Thienobenzodiazepine
Olanzapine (an antipsychotic drug) has shown 
in phase III studies efficacy in the prevention of the 
N&V that occurs despite optimal prophylaxis, which 
results from the antagonistic effect of the drug against 
5-HT3 and the D2 as well as against other receptors 
that participate in the development of N&V (e.g. his-
taminic or muscarinic) [12]. The drug should be used 
in combination with setron and dexamethasone [4, 12]. 
Olanzapine may induce sleep disturbances and tiredness 
(precaution is recommended in elderly persons), and it 
favours the occurrence of the QT-interval prolongation 
on ECG. The drug should not be used in combination 
with metoclopramide (risk of extrapyramidal reactions).
The objective efficacy of other benzodiazepines in 
the prevention of N&V is minimal. The sedative activity 
of benzodiazepines is much more important. It may be 
used in the prophylaxis of anticipatory and prolonged 
N&V as well as in complaints induced by CTH with 
a low emetogenic potential. 
Preventive management 
General rules of management
The general rules of management are generally ac-
cepted. They include the necessity to:
 — evaluate the emetogenic potential of the planned 
CTH (necessity to define the risk extent determined 
by the drug with the highest emetogenic potential; 
the superadditive effect of combinations of some 
cytostatic drugs should also be considered);
 — define the individual characteristic of the patient in 
the aspect of the risk of developing N&V;
 — select the antiemetic drugs based on the evaluation 
of the emetogenic potential of the CTH regimen and 
on the individual patient characteristics, as well as 
on the potential side effects of the antiemetic drugs 
(in the case of CTH scheduled for several days, the 
evaluation of the N&V risk on each day of the thera-
py and an appropriate choice of antiemetic therapy);
 — use a combined antiemetic therapy with considera-
tion of the lowest efficient doses of the drugs;
 — use preferably drugs that are administered orally;
 — avoid using or to decrease the dose of corticosteroids 
in the case of their concomitant use in the CTH 
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Table 6. A prophylactic antiemetic management depending on the emetogenic potential of the chemotherapy (CTH)
The risk of nausea and vomiting Management
High 5-HT3 antagonist on day 1
+
Dexamethasone 12 mg on day 1 and 8 mg on days 2–4
+
NK-1 antagonist — netupitant on day 1 (a drug in a combined formulation with 
palonosetron)* or aprepitant on days 1–3
The recent ASCO guideline [5] indicates that use of the 4-drug regimen  
(5-HT3 antagonist, dexamethasone, NK-1 antagonist and olanzapine) may be 
associated with greater benefits
Moderate 5-HT3 antagonist on day 1
+
Dexamethasone 8 mg on days 1–3
Low Dexamethasone 4–8 mg on day 1
Minimal Only when the symptoms are present
*In the case of netupitant, it is not necessary to use the 5-HT3 antagonist (netupitant in a combined formulation with palonosetron)
regimen or to use an NK-1 receptor antagonist in 
the antiemetic management;
 — evaluate the efficacy of the antiemetic therapy after 
each cycle of CTH;
 — consider other causes of N&V in the differential 
diagnostics (e.g. gastrointestinal tract obstruction, 
liver impairment, metastases to the CNS or to the 
liver, oedema of the brain, neoplastic involvement 
of meninges, hypercalcaemia or any other electro-
lyte imbalances, uraemia, use of opioids or of some 
other drugs);
 — use rescue therapy in case of a documented inefficacy 
of the first-line preventive therapy.
It is very important to follow the rules of the cost-ef-
fectiveness of the therapy. The ineffective escalation of 
the 5-HT3 and NK-1 inhibitors should be avoided and 
the time of the therapy with these drugs should not be 
prolonged (the use of 5-HT3 inhibitor on day 2 and 
on consecutive days after the completion of CTH is il-
legitimate). We should remember that the 5-HT3 and 
NK-1 inhibitors are not effective in the therapy of N&V 
induced by factors other than the antineoplastic therapy 
(except for setrons in postoperative N&V).
The schedule of preventive management depending 
on the emetogenic potential of the CTH is presented 
in Table 6. 
The detailed principles of antiemetic management
In the case of CTH with high emetogenic poten-
tial, combined use of 5-HT3 inhibitor, anti-NK-1, and 
a corticosteroid is recommended [4, 5]. Preventive 
management should be used in every clinical situation. 
The validity of the administration of NK-1 antagonists 
in case of CTH containing cisplatin at a dose exceed-
ing 50 mg/m2 and in regimens with anthracyclines and 
cyclophosphamide is based on clinical proof with the 
highest level of evidence (I, A). 
The administration of the NK-1 antagonist in combi-
nation with anti-5HT3 and dexamethasone may be con-
sidered in patients who receive carboplatin-containing 
CTH (carboplatin dose higher than 4 AUC) (I, B), be-
cause higher response rate (no N&V) of combination of 
anti-NK-1 and anti-5-HT3 drugs has been demonstrated 
in randomised trials. However, the differences have not 
always been significant [4].
The results of the randomised clinical trials do not 
justify the concomitant use of 5-HT3 and NK-1 an-
tagonists and dexamethasone in patients who receive 
oxaliplatin in the chemotherapeutic schedule [4, 5].
Patients who receive CTH with high emetogenic 
potential usually develop intensive early and late N&V. 
The early N&V may be completely controlled. Effective 
control of early N&V is important because it conditions 
the absence of the delayed symptoms in about 75% of 
patients. The efficacy of the prevention of late N&V 
is lower. We should remember that the escalation of 
the dose and the prolongation of the duration of the 
antiemetic therapy beyond the recommended time does 
not improve its efficacy. The repeated administration 
of the 5-HT3 antagonist on consecutive days is justified 
only for dose fractionationation of the drug with high 
emetogenic potential (antiemetic drugs should be used 
sufficiently for the emetogenic potential of the CTH 
administered on a particular day and, if necessary, 
during the two days after the completion of this type 
of CTH) [4, 5]. 
The management of N&V induced by CTH with 
moderate emetogenic potential is differentiated. The 
N&V prophylaxis is obligatory in all patients at the 
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Table 7. The emetogenic potential of radiotherapy (RT) 
depending on the irradiated field [13]
Grade  
of hazard
Irradiated field 
High TBI
Moderate HBI
RT of the upper abdomen and of the pelvis 
RT — a lower field
RT CNS
Low RT chest 
Radiosurgery CNS
Minimal Othertypes of RT
TBI (total-body irradiation) — RT of the total body; HBI (hemi-body irradia-
tion) — RT of half of the body 
beginning of the CTH (I, A). The majority of the CTH 
regimens are characterised by a relatively high risk of 
early N&V while the probability of late symptoms is 
considerably lower. For this reason, the prophylactic 
use of the 5-HT3 receptor antagonist (only on the day 
of CTH administration; many medical societies recom-
mend palonosetron) and of the corticosteroid as well 
addition of benzodiazepine or chlorpernazine is recom-
mended (I, A). The exceptions are regimens containing 
doxorubicin or epirubicin and cyclophosphamide (a high 
risk of early and late N&V — the antiemetic therapy in 
this case is the same as the one used in the CTH with 
high emetogenic potential) [4, 5]. 
In case of CTH with low emetogenic potential it is 
advisable to use N&V prophylaxis in form of monother-
apy with corticosteroids. Administration of more active 
drugs or prolongation of the prophylactic management is 
indicated only in the case of inefficiency of the standard 
procedures (I, A) [4, 5]. 
The chemotherapy with minimal emetogenic po-
tential does not initially require any pharmacological 
prevention of N&V.
The principles of management in case of anticipatory 
N&V are completely different. Due to the psychogenic 
background and a different pathomechanism, classical 
drugs are useless. Sedative drugs or psychotherapy may 
alleviate the symptoms, but the most effective prophy-
laxis is good control of early and late symptoms.
Supportive therapy constitutes and important part of 
the management. In case of severe N&V, patients should 
receive appropriate hydration and correction of the elec-
trolyte imbalance. The use of H2 receptor blockers may 
be effective (e.g. ranitidine, which alleviates the symptoms 
of the biliary reflux to the stomach during vomiting).
Rescue management
The principle of rescue management in case of fail-
ure of the preventive therapy is the administration of 
drugs with a different mechanism of action (II, C). In 
patients who receive CTH with low emetogenic poten-
tial, 5-HT3 receptor inhibitors are mostly recommended, 
while during chemotherapy with moderate emetogenic 
risk the use of NK-1 antagonist is recommended (if not 
initially used). The use of chloropenazine, benzodiaz-
epine, or metoclopramide may also be considered. Lack 
control of the N&V during CTH with high emetogenic 
potential constitutes an especially difficult clinical 
situation, particularly when the most active antiemetic 
drugs have already been used initially. The escalation 
of the doses of 5-HT3 and NK-1 receptor inhibitors 
and the prolongation of the time of administration 
of these drugs does not improve the control of N&V. 
There is no defined standard of management; the use 
of setron with different pharmacological proprieties 
(e.g. palonosetron), the addition of supportive drugs, 
or the use of fractionated CTH (mostly cisplatin) may 
be considered. If CTH is administered with palliative 
intention and the N&V is not controlled and significantly 
decreases the quality of the patient’s life, then the use 
of a CTH regimen with lower emetogenic risk may be 
a good solution [4, 5].
Radiotherapy-related nausea and 
vomiting
Pathomechanism and risk factors
The mechanism of the development of N&V during 
radiotherapy is not completely clear. During the irra-
diation of the abdominal cavity the major mechanisms 
are the stimulation of the mucosal receptors and a con-
secutive transduction of the signal through the neuro-
transmitters (mostly serotonin and dopamine) to the 
CNS. On the other hand, brain irradiation my result in 
direct interaction with the trigger centre receptors [13]. 
The emetogenic potential of RT — depending on the 
strategy and the irradiation field — is presented in 
Table 7 (II, A).
Management 
The prophylactic use of the antiemetic drugs — an-
tagonists of the 5-HT3 receptor and of the corticoster-
oids — is indicated only in the case of the RT with high 
emetogenic risk (in clinical practice in TBI). In patients 
undergoing a TBI it is recommended that a single dose 
of a 5-HT3 receptor antagonist be administered in 
a standard dose before and at least during the first day 
after the RT in combination with dexamethasone or 
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without corticosteroid. In other situations, preventive 
therapy based on corticosteroids, metoclopramide an-
tihistaminic drugs, benzodiazepines (and in the case of 
no effect, also of the inhibitors of the 5-HT3 receptor) 
should be started only in patients who have symptoms 
(II, A) [4, 5, 13]. 
References
1. Herrstedt J. Antiemetics: an update and the MASCC guidelines ap-
plied in clinical practice. Nat Clin Pract Oncol. 2008; 5(1): 32–43, doi: 
10.1038/ncponc1021, indexed in Pubmed: 18097455.
2. Basch E, Prestrud AA, Hesketh P, et al. Antiemetics: American Society 
of ical ogy ical Practice Guideline Update. J Clin Oncol. 2011; 29: 
4189–4198.
3. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic 
agents and definition of antineoplastic agent emetogenicity--state of 
the art. Support Care Cancer. 2011; 19 Suppl 1: S43–S47, doi: 10.1007/ 
/s00520-010-1003-x, indexed in Pubmed: 20972805.
4. Roila F, Molassiotis A, Herrstedt J, et al. participants of the MASCC/ 
/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and 
ESMO guideline update for the prevention of chemotherapy- and radio-
therapy-induced nausea and vomiting and of nausea and vomiting in 
advanced cancer patients. Ann Oncol. 2016; 27(suppl 5): v119–v133, 
doi: 10.1093/annonc/mdw270, indexed in Pubmed: 27664248.
5. Hesketh PJ, Bohlke K, Lyman GH, et al. American Society of Clinical 
Oncology. Antiemetics: American Society of Clinical Oncology Focused 
Guideline Update. J Clin Oncol. 2016; 34(4): 381–386, doi: 10.1200/ 
/JCO.2015.64.3635, indexed in Pubmed: 26527784.
6. Dranitsaris G, Molassiotis A, Clemons M, et al. The development of 
a prediction tool to identify cancer patients at high risk for chemothera-
py-induced nausea and vomiting. Ann Oncol. 2017; 28(6): 1260–1267, 
doi: 10.1093/annonc/mdx100, indexed in Pubmed: 28398530.
7. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the 
efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-
-induced emesis. Support Care Cancer. 2007; 15(9): 1023–1033, doi: 
10.1007/s00520-006-0186-7, indexed in Pubmed: 17205281.
8. Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly 
emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 
2010(1): CD006272, doi: 10.1002/14651858.CD006272.pub2, indexed 
in Pubmed: 20091591.
9. Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) 
compared to other serotonin inhibitors (5-HT3R) in preventing che-
motherapy-induced nausea and vomiting (CINV) in patients receiving 
moderately or highly emetogenic (MoHE) treatment: systematic review 
and meta-analysis. Support Care Cancer. 2011; 19(6): 823–832, doi: 
10.1007/s00520-010-0908-8, indexed in Pubmed: 20495832.
10. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor 
antagonists for chemotherapy-induced nausea and vomiting: a sys-
tematic review. J Natl Cancer Inst. 2012; 104(17): 1280–1292, doi: 
10.1093/jnci/djs335, indexed in Pubmed: 22911671.
11. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of 
chemotherapy-induced nausea and vomiting (CINV): a comprehensive 
review. Ann Oncol. 2015; 26(6): 1081–1090, doi: 10.1093/annonc/ 
/mdv138, indexed in Pubmed: 25755107.
12. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of 
Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 
375(2): 134–142, doi: 10.1056/NEJMoa1515725, indexed in Pubmed: 
27410922.
13. Feyer P, Maranzano E, Molasiotis A et al. MASCC/ESMO. Radiotherapy-
-induced nausea and vomiting (RINV): antiemetic guidelines. Support 
Care Cancer. 2005; 13(2): 122–128, doi: 10.1007/s00520-004-0705-3, 
indexed in Pubmed: 15592688.
